A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1567-1572

  Caver, T E ^a   Lockey, T D ^a   Srinivas, R V ^a   Webster, R G ^a,b   Hurwitz, J L ^a,b,c  

^a St Jude Children's Research Institute   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Cocktail; DNA; HIV envelope; Protein; Vaccinia virus

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; RECOMBINANT DNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOSTIMULATION; INTERMETHOD COMPARISON; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHUTTLE VECTOR; TREATMENT OUTCOME; VACCINATION; VACCINIA VIRUS;

AIDS VACCINES; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, ENV; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; MICE; MICE, INBRED C57BL; VACCINES, DNA; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0033577255     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00355-7     Document Type: Article

References (25)

1. Kundig T.M., Kalberer C.P., Hengartner H., Zinkernagel R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine. 11:1993;1154-1158.
2. Boyer J.D., Ugen K.E., Wang B., Agadianyan M., Gilbert L., Bagarazzi M.L.et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3:1997;352-526.
3. Richmond JFL, Mustafa F, Montefiori D, Lu S, Santoro JC, Hurwitz JL et al. Use of DNA-immunization to elicit antibody to primary and monocyte/macrophage-tropic HIV-1 Envs. Conference on Advances in AIDS vaccine development 1996, 8th Annual Meeting, p. 204 (abstract).
4. Hu S.-L., Fultz P.N., McClure H.M., Eichberg J.W., Thomas E.K., Zarling J.et al. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 328:1987;721-723.
5. Lu S., Arthos J., Montefiori D.C., Yasutomi Y., Manson K., Mustafa F.et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol. 70:1996;3978-3991.
6. Lu S., Manson K., Wyand M., Robinson H.L. SIV DNA vaccine trial in macaques: Post-challenge necropsy in vaccine and control groups. Vaccine. 15:1997;920-923.
7. Richmond J.F.L., Mustafa F., Lu S., Santoro J.C., Weng J., O'Connellet al. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology. 230:1997;265-274.
8. Fuller D.H., Corb M.M., Barnett S., Steimer K., Haynes J.R. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine. 15:1997;924-926.
9. Fuller D.H., Simpson L., Cole K.S., Clements J.E., Panicali D.L., Montelaro R.C.et al. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol. 75:1997;389-396.
10. Kim J.J., Ayyavoo V., Bagarazzi M.L., Chattergoon M., Boyer J.D., Wang B.et al. Development of a multicomponent candidate vaccine for HIV-1. Vaccine. 15:1997;879-883.
11. Newman M.J., Wu J.-Y., Gardner B.H., Anderson C.A., Kensil C.R., Recchia J.et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine. 15:1997;1001-1007.
12. Prayaga S.K., Ford M.J., Haynes J.R. Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization. Vaccine. 15:1997;1349-1352.
13. Okuda K., Xin K.Q., Tsuji T., Bukawa H., Tanaka S., Koff W.C.et al. DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity. Vaccine. 15:1997;1049-1056.
14. Ratner L., Haseltine W., Patarca R., Livak K.J., Starcich B., Josephs S.F.et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 313:1985;277-284.
15. Hallenberger S., Tucker S.P., Owens R.J., Bernstein H.B., Compans R.W. Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. Virology. 193:1993;510-514.
16. Neutralizing antibody evaluation: Infectivity reduction assay. Division of AIDS Virology Manual for HIV Laboratories, National Institutes of Health Division of AIDS (Bethesda, MD) 1997, p. 182-186.
17. Larché M., Manzo A.R., Hurwitz J.L. Environmental and allele-specific influences on T-cell receptor gene rearrangement: Skewed alpha, delta and gamma gene rearrangement patterns in chimeric mice. Eur J Immunol. 21:1991;2943-2949.
18. Wyatt W., Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens and immunogens. Science. 280:1998;1884-1888.
19. Corey L., McElrath M.J., Weinhold K., Matthews T., Stablein D., Graham B.et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis. 177:1998;301-309.
20. Graham B.S., McElrath M.J., Connor R.I., Schwartz D.H., Gorse G.J., Keefer M.C.et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. J Infect Dis. 177:1998;310-319.
21. Berman P.W., Gray A.M., Wrin T., Vennari J.C., Eastman D.J., Nakamura G.R.et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis. 176:1997;384-397.
22. McElrath M.J., Corey L., Greenberg P.D., Matthews T.J., Montefiori D.C., Rowen L.et al. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci (USA). 93:1996;3972-3977.
23. Rencher S.D., Hurwitz J.L. Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3-specific and non-V3-specific antibodies. J Aquir Immune Defic Syndr. 16:1997;69-73.
24. Rencher S.D., Slobod K.S., Dawson D., Lockey T.D., Hurwitz J.L. Does the key to a successful HIV vaccine lie among the envelope sequences of infected individuals? AIDS Res Hum Retroviruses. 11:1995;1131-1135.
25. Rencher S.D., Lockey T.D., Srinivas R.V., Owens R.J., Hurwitz J.L. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Vaccine. 15:1997;265-272.